SOCS2 protects against chemical-induced hepatocellular carcinoma progression by modulating inflammation and cell proliferation in the liver.

[1]  R. Masuzaki,et al.  Suppressors of Cytokine Signaling and Hepatocellular Carcinoma , 2022, Cancers.

[2]  Clifford Liongue,et al.  SOCS Proteins in Immunity, Inflammatory Diseases, and Immune-Related Cancer , 2021, Frontiers in Medicine.

[3]  Zhangzhi Zhu,et al.  Identification of potential crucial genes associated with the pathogenesis and prognosis of liver hepatocellular carcinoma , 2020, Journal of Clinical Pathology.

[4]  S. Ramanathan,et al.  Prognostic significance of SOCS1 and SOCS3 tumor suppressors and oncogenic signaling pathway genes in hepatocellular carcinoma , 2020, BMC Cancer.

[5]  B. Carr,et al.  Inflammatory Mechanisms of HCC Development , 2020, Cancers.

[6]  G. Ferbeyre,et al.  STAT3 and STAT5 Activation in Solid Cancers , 2019, Cancers.

[7]  P. Sutphin,et al.  Staging systems of hepatocellular carcinoma: A review , 2018, Indian Journal of Gastroenterology.

[8]  D. Frank,et al.  Targeting Oncogenic Transcription Factors: Therapeutic Implications of Endogenous STAT Inhibitors. , 2017, Trends in cancer.

[9]  Stefan Rose-John,et al.  IL-6 pathway in the liver: From physiopathology to therapy. , 2016, Journal of hepatology.

[10]  L. Terracciano,et al.  Histopathology of hepatocellular carcinoma. , 2014, World journal of gastroenterology.

[11]  S. Haan,et al.  Identification of SOCS2 and SOCS6 as biomarkers in human colorectal cancer , 2014, British Journal of Cancer.

[12]  Alisha M. Mendonsa,et al.  Hepatocellular Proliferation Correlates with Inflammatory Cell and Cytokine Changes in a Murine Model of Nonalchoholic Fatty Liver Disease , 2013, PloS one.

[13]  Y. Tu,et al.  Reduced expression of SOCS2 and SOCS6 in hepatocellular carcinoma correlates with aggressive tumor progression and poor prognosis , 2013, Molecular and Cellular Biochemistry.

[14]  G. Norstedt,et al.  SOCS2 deletion protects against hepatic steatosis but worsens insulin resistance in high‐fat‐diet‐fed mice , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  G. Trinchieri.  Cancer and inflammation: an old intuition with rapidly evolving new concepts. , 2012, Annual review of immunology.

[16]  M. Karin,et al.  Tumor promotion via injury- and death-induced inflammation. , 2011, Immunity.

[17]  Kuen-Feng Chen,et al.  Activation of Phosphatidylinositol 3-Kinase/Akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma Cells , 2011, Journal of Pharmacology and Experimental Therapeutics.

[18]  Chiun Hsu,et al.  Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives , 2010, Journal of Gastroenterology.

[19]  P. Lund,et al.  Suppressor of cytokine signaling-2 gene disruption promotes Apc(Min/+) tumorigenesis and activator protein-1 activation. , 2010, The American journal of pathology.

[20]  T. Okanoue,et al.  Blockade of interleukin-6 signaling enhances hepatic steatosis but improves liver injury in methionine choline-deficient diet-fed mice , 2010, Laboratory Investigation.

[21]  F. Heindryckx,et al.  Experimental mouse models for hepatocellular carcinoma research , 2009, International journal of experimental pathology.

[22]  L. Hennighausen,et al.  Loss of STAT5 causes liver fibrosis and cancer development through increased TGF-β and STAT3 activation , 2009, The Journal of experimental medicine.

[23]  S. Friedman,et al.  Experimental models of hepatocellular carcinoma. , 2008, Journal of hepatology.

[24]  F. Révillion,et al.  Favorable prognostic value of SOCS2 and IGF-I in breast cancer , 2007, BMC Cancer.

[25]  Masato Kubo,et al.  SOCS proteins, cytokine signalling and immune regulation , 2007, Nature Reviews Immunology.

[26]  Tania Nolan,et al.  Quantification of mRNA using real-time RT-PCR , 2006, Nature Protocols.

[27]  S. Thorgeirsson,et al.  Hematopoietic cells as hepatocyte stem cells: A critical review of the evidence , 2006, Hepatology.

[28]  D. Santini,et al.  Suppressor of cytokine signalling 2 (SOCS-2) expression in breast carcinoma , 2005, Journal of Clinical Pathology.

[29]  Carmen Z. Michaylira,et al.  Suppressor of cytokine signaling-2 modulates the fibrogenic actions of GH and IGF-I in intestinal mesenchymal cells. , 2005, American journal of physiology. Gastrointestinal and liver physiology.

[30]  Michael Karin,et al.  IKKβ Couples Hepatocyte Death to Cytokine-Driven Compensatory Proliferation that Promotes Chemical Hepatocarcinogenesis , 2005, Cell.

[31]  Eric B Haura,et al.  Mechanisms of Disease: insights into the emerging role of signal transducers and activators of transcription in cancer , 2005, Nature Clinical Practice Oncology.

[32]  Michael Karin,et al.  Reactive Oxygen Species Promote TNFα-Induced Death and Sustained JNK Activation by Inhibiting MAP Kinase Phosphatases , 2005, Cell.

[33]  W. Alexander,et al.  Gigantism in mice lacking suppressor of cytokine signalling-2 , 2000, Nature.

[34]  K. Movahedi,et al.  Tissue-resident versus monocyte-derived macrophages in the tumor microenvironment. , 2016, Biochimica et biophysica acta.

[35]  S. Haan,et al.  SOCS2: physiological and pathological functions. , 2016, Frontiers in bioscience.

[36]  G. Jenster,et al.  SOCS2 mediates the cross talk between androgen and growth hormone signaling in prostate cancer. , 2014, Carcinogenesis.

[37]  A. Jemal,et al.  Global Cancer Statistics , 2011 .